Urethral toxicity vs. cancer control-Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer

Brachytherapy

Volumn 10, Issue 4, 2011, Pages 286-294

  Ghadjar, Pirus ^a   Rentsch, Cyrill A ^b   Isaak, Bernhard ^a   Behrensmeier, Frank ^a   Thalmann, George N ^a   Aebersold, Daniel M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Brachytherapy; IMRT; Prostate cancer; Toxicity

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR;

ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; COMMON TOXICITY CRITERIA SCALE; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL TOXICITY; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; MALE SEXUAL DYSFUNCTION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; SEXUAL FUNCTION; TUMOR CLASSIFICATION; URETHRA DISEASE; UROGENITAL TRACT DISEASE;

AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; URETER;

EID: 79958802087     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2010.09.005     Document Type: Article

References (26)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
2. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
3. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
4. Zietman Al, DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005, 294:1233-1239.
5. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1960-1966.
6. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998, 41:83-92.
7. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:980-988.
8. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166:876-881.
9. Brenner D.J., Hall E.J. Fractionation and protraction for radio-therapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101.
10. Martinez A.A., Gustafson G., Gonzalez J., et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:316-327.
11. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1048-1055.
12. Deger S., Boehmer D., Roigas J., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005, 47:441-448.
13. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316.
14. Astrom L., Pedersen D., Mercke C., et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localized prostate cancer. Radiother Oncol 2005, 74:157-161.
15. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006, 66:416-423.
16. Ghadjar P., Matzinger O., Isaak B., et al. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol 2009, 91:237-242.
17. Roach M. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:1923-1924.
18. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
19. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958, 53:457-481.
20. Hoskin P.J., Bownes P.J., Ostler P., et al. High dose rate afterloading brachytherapy for prostate cancer: Catheter and gland movement between fractions. Radiother Oncol 2003, 68:285-288.
21. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002, 360:103-108.
22. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2572.
23. Zapatero A., Valcarcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 2005, 23:6561-6568.
24. Zelefsky M.J., Yamada Y., Kollmeier M.A., et al. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008, 53:1172-1179.
25. Nguyen K.H., Horwitz E.M., Hanlon A.L., et al. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 57:377-383.
26. Sullivan L., Williams S.G., Tai K.H., et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009, 91:232-236.